Insight Molecular Diagnostics
IMDX
56 hedge funds and large institutions have $58.2M invested in Insight Molecular Diagnostics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 9 closing their positions.
46% more capital invested
Capital invested by funds: $39.9M → $58.2M (+$18.4M)
0.44% more ownership
Funds ownership: 1.83% → 2.27% (+0.44%)
0% more funds holding
Funds holding: 56 → 56 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$10.3M |
| 2 |
BC
Broadwood Capital
New York
|
+$2.12M |
| 3 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$451K |
| 4 |
PM
Penbrook Management
New York
|
+$319K |
| 5 |
Barclays
London,
United Kingdom
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$711K |
| 2 |
DAM
Doheny Asset Management
Los Angeles,
California
|
-$295K |
| 3 |
Millennium Management
New York
|
-$105K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$85K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$73K |
IMDX Hedge Fund Activity: Q4 2019 in Review
56 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2019, worth a combined $58.2M — up 46% from $39.9M a quarter earlier.
Fund positioning in IMDX was balanced in Q4 2019: 9 funds opened new positions, 9 closed out, 15 added to existing stakes and 19 trimmed.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $10.3M. The largest seller was Emerald Mutual Fund Advisers Trust, cutting an estimated $711K.
- 56 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $58.2M of Insight Molecular Diagnostics stock for Q4 2019, up 46% quarter-over-quarter.
- 9 funds opened new Insight Molecular Diagnostics positions in Q4 2019 and 9 closed out, a net change of 0 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2019 was Pura Vida Investments, an estimated $10.3M added.
- The largest Insight Molecular Diagnostics seller in Q4 2019 was Emerald Mutual Fund Advisers Trust, an estimated $711K sold.
Based on aggregated 13F filings for Q4 2019.